Related Experiment Video
Updated: May 10, 2026
05:25
Simultaneous Detection of Different Antibody Classes in a Multiplexed Serological Test
Published on: July 14, 2023
[Equivalency examinations for foreign physicians in Baden-Wuerttemberg].
N Farhan1, A Wiesemann2, M Wirsching3
1Abteilung für Neurochirurgie, Universitätsklinikum Freiburg.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))
|June 20, 2013
Summary
Foreign doctors seeking medical licenses in Germany face challenges with the equivalency exam. This study identifies issues in exam structure, content, and candidate/examiner factors, proposing improvements for a more transparent and standardized process.
Area of Science:
- Medical Education
- Professional Licensure
- International Medical Graduates
Context:
- Increasing number of foreign-trained doctors practicing in Germany.
- Equivalency examination required for medical licensure for non-EU doctors.
- Varied procedures across German federal states.
Purpose:
- Identify problems in the current medical equivalency examination process.
- Propose solutions to enhance the quality and standardization of the exam.
- Address challenges faced by foreign doctors in obtaining German medical licenses.
Summary:
- Focus group analysis of difficulties in the medical equivalency exam for foreign doctors.
- Identified deficits in subject knowledge, communication skills, and exam procedures.
- Categorized issues into exam structure/content, examiners, and candidates.
Impact:
- Recommendations developed with the State Examination Office Stuttgart for process optimization.
- Proposals include developing a special curriculum and recruiting more examiners.
- Aims to increase transparency and facilitate Germany-wide standardization of the medical equivalency exam.
Related Concept Videos
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:17Equivalence: In Vitro and In Vivo Bioequivalence
Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts. Pharmaceutical...
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...